29 April 2026 : Database Analysis
Telomerase-Associated Genes as Prognostic Markers in High-Grade Serous Ovarian Cancer
Xiaohua Wang
ABCEG 1, Shuyu Han CDF 1, Xi Wang BC 1, Yanwei Guo ACDEF 2*
DOI: 10.12659/MSM.951804
Med Sci Monit 2026; 32:e951804
Figure 10 Differences in tumor mutation burden and drug sensitivity between the high-risk and low-risk groups. (A) Top 20 genes with the highest mutation frequency in the high-risk group. (B) Top 20 genes with the highest mutation frequency in the low-risk group. Differential drug sensitivity of (C) Afatinib_1032, (D) Buparlisib_1873, (E) PD0325901_1060, (F) Pictilisib_1058, (G) Sabutoclax_1849, (H) Trametinib_1372, (I) AZD5582_1617, (J) Entinostat_1593, and (K) AGI-6780_1643 between the high-risk and low-risk groups.